PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan.
PSMA-PET imaging and <sup>177</sup>Lu-vipivotide therapy are advancing in prostate cancer care, but further research is needed to confirm their long-term benefits.
Where it sits
this study against the rest of the vipivotide corpusSummary and findings
This review discusses the role of prostate-specific membrane antigen (PSMA) in prostate cancer imaging and therapy, particularly focusing on the use of <sup>177</sup>Lu-vipivotide tetraxetan. It highlights the integration of PSMA-PET/CT in clinical guidelines and the current status of PSMA-targeted therapies. The implications for implementation in Japan are also addressed.
Abstract
Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein markedly overexpressed on prostate cancer cells, enabling a single molecular target to support both positron emission tomography (PET) imaging and targeted radionuclide therapy. Over the past decade, PSMA-PET/CT has been incorporated into international guidelines for primary staging of high-risk prostate cancer and for biochemical recurrence, with the landmark proPSMA trial establishing its diagnostic superiority over conventional imaging; whether PSMA-PET-guided management improves long-term oncologic outcomes, however, remains an open question addressable only by prospective PSMA-specific trials. On the therapeutic side, <sup>177</sup>Lu-PSMA-617 has become a standard treatment option for metastatic castration-resistant prostate cancer (mCRPC) after androgen-receptor pathway inhibitor (ARPI) and taxane chemotherapy, and is moving into earlier lines of disease. Alpha-emitting and next-generation ligands, together with quantitative whole-body imaging and artificial intelligence, are redefining both patient selection and response assessment, although randomized evidence for many of these approaches remains limited. In Japan, the concurrent 2025 approval of <sup>177</sup>Lu-vipivotide tetraxetan and its companion PSMA diagnostic has initiated a national roll-out that will depend on a hub-and-spoke framework of regional PSMA-PET centers and therapy spokes, a prepared nuclear medicine workforce, and domestic registries to refine Japanese-specific evidence. This review summarizes the current clinical evidence for PSMA-PET/CT and <sup>177</sup>Lu-PSMA radioligand therapy, highlights interpretive and implementation pitfalls, and outlines practical priorities for the Japanese clinical and academic community.
Background
This paper addresses the clinical implications of prostate-specific membrane antigen (PSMA) in prostate cancer, particularly its role in imaging and therapy. PSMA is significantly overexpressed in prostate cancer cells, making it a valuable target for both diagnostic and therapeutic strategies. The integration of PSMA-PET/CT into clinical guidelines marks a significant advancement, but the long-term benefits of PSMA-guided management are still uncertain and require further investigation.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
While PSMA-PET imaging has shown diagnostic superiority, the review indicates that the actual impact on long-term oncologic outcomes is still an open question. The introduction of <sup>177</sup>Lu-vipivotide tetraxetan in Japan represents a significant development, but the evidence supporting its efficacy is not yet robust. The need for prospective trials is critical to establish clinically meaningful outcomes.
Key findings
- PSMA-PET/CT has been incorporated into international guidelines for primary staging of high-risk prostate cancer.
- The proPSMA trial established the diagnostic superiority of PSMA-PET over conventional imaging.
- <sup>177</sup>Lu-PSMA-617 has become a standard treatment option for metastatic castration-resistant prostate cancer after ARPI and taxane chemotherapy.
- Randomized evidence for many PSMA-related approaches remains limited.
Limitations
- No specific numeric outcomes or data provided.
- Limited randomized evidence for many PSMA-related approaches.
- Emphasis on the need for prospective trials to evaluate long-term outcomes.